Latest International Markets News

BetMakers Technology Group reports a robust Q2 FY26 with 14.1% revenue growth and a $2.7 million positive Adjusted EBITDA, underpinned by key partnerships and margin expansion.

Acrux Limited reports solid revenue growth and increased cash reserves in the December quarter, driven by expanding its topical generics portfolio in the US and strategic moves into female Hormone Replacement Therapy.

Change Financial Limited has reported a record revenue quarter driven by its Vertexon platform growth and new client wins, prompting an upgrade to its FY26 financial guidance.

MyEco Group Ltd has reported record quarterly sales of its MyEcoBag® products, alongside improved gross margins and a significant reduction in operating cash outflows following a strategic operational restructure.

Eden Innovations has significantly reduced its debt burden and secured fresh capital, while expanding sales and trials of its advanced concrete additives across key international markets.

Syrah Resources delivered a record quarter with a 34% rise in natural graphite production and advancing anode material qualification at its Vidalia facility, while navigating evolving US trade policies that could reshape its market dynamics.

Firebrick Pharma has commenced commercial manufacturing and export of its new Nasodine Throat Spray, marking a significant step in its international expansion. The company also reported a 15% increase in cash sales and reduced operating costs, signalling improving financial health.

Global Uranium and Enrichment Limited shareholders have decisively approved Snow Lake Resources’ acquisition schemes, setting the stage for Federal Court approval and a significant market transition.

Singular Health Group has advanced its U.S. commercial footprint with the deployment of 500 new licences under its PNS contract and secured FDA clearance for its cloud-based 3DICOM MD® platform, positioning the company for significant growth.

Biome Australia Limited has delivered its strongest quarterly financial performance to date, with sales revenue surging 41% year-on-year to $6.5 million and maintaining eight consecutive quarters of positive EBITDA.

Echo IQ has completed clinical validation of its EchoSolv HF heart failure detection software with the Mayo Clinic Platform, achieving outstanding accuracy. The company has now formally submitted its FDA 510(k) clearance application, positioning itself for significant commercial expansion in the US healthcare market.

Life360 has reported its strongest quarter ever, with record user and subscriber growth in Q4 2025, surpassing full-year revenue and EBITDA guidance. The company forecasts continued momentum with 20% user growth expected in 2026.